A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT ID: NCT06064877
Last Updated: 2025-04-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
410 participants
INTERVENTIONAL
2024-01-11
2027-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary hypothesis is that ficlatuzumab combined with cetuximab is superior to cetuximab alone in terms of progression-free survival and/or overall survival.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
NCT03422536
Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT02277197
Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
NCT05057247
Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
NCT00494182
Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT02277184
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1 (Investigational Arm: ficlatuzumab plus cetuximab)
Intravenous (IV) ficlatuzumab dose A on Day 1 (D1) and D15 of each 28-day cycle IV cetuximab on D1 and D15 of each 28-day cycle
Ficlatuzumab
Ficlatuzumab (AV-299) is a humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G1 (IgG1) monoclonal antibody (mAb).
Cetuximab
Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.
Arm 2 (Investigational Arm: ficlatuzumab plus cetuximab)
IV ficlatuzumab dose B on D1 and D15 of each 28-day cycle IV cetuximab on D1 and D15 of each 28-day cycle
Ficlatuzumab
Ficlatuzumab (AV-299) is a humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G1 (IgG1) monoclonal antibody (mAb).
Cetuximab
Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.
Arm 3 (Comparator Arm: placebo plus cetuximab)
IV placebo (saline, ficlatuzumab-matched) on D1 and D15 of each 28-day cycle IV cetuximab on D1 and D15 of each 28-day cycle
Cetuximab
Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.
Placebo
Placebo for this study will be normal saline
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ficlatuzumab
Ficlatuzumab (AV-299) is a humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G1 (IgG1) monoclonal antibody (mAb).
Cetuximab
Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.
Placebo
Placebo for this study will be normal saline
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically and/or cytologically confirmed primary diagnosis of R/M HNSCC
* Participants with oropharyngeal cancer will be required to have proof of p16 negative status submitted on the basis of a pathology report
* At least 1 measurable lesion by contrast CT or MRI scan according to RECIST v.1.1. Such lesions must not have been previously irradiated; if the measurable lesion(s) has been irradiated, clear progression must be documented
* Participants must have failed prior therapy with an anti-PD-1/PD-L1 ICI and with platinum-based chemotherapy administered in combination or sequentially, in either the locally advanced or R/M setting. Failure of prior treatment may be due to progression of disease or intolerance to treatment
* Patient's tumor must be considered inoperable and incurable
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with a life expectancy of at least 12 weeks
* For women of childbearing potential (WOCBP), documentation of negative serum pregnancy test within 30 days of randomization
* For WOCBP and male participants whose sexual partners are of childbearing potential, agreement to use an effective method of contraception during the study and for at least 5 months after the last dose of study treatment. Birth control methods which may be considered highly effective include methods that achieve a failure rate of less than 1% per year when used consistently and correctly.
* Ability to give written informed consent and comply with protocol requirements
* Patients with feeding tubes are eligible for the study.
* Archived tissue sample must be submitted to the Sponsor-designated laboratory within 60 days of randomization for c-Met analysis (if a tissue sample is not available, a fresh biopsy may be required prior to enrollment)
Exclusion Criteria
* History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent or cetuximab
* Known or suspected untreated and uncontrolled brain metastases or leptomeningeal carcinomatosis Note: Participants with locally treated brain metastases are eligible provided 2 weeks have elapsed since local therapy. Participants are allowed to continue steroid taper during the start of study treatment.
* Prior treatment with any other investigational drug or biologic agent or radiation therapy before a washout has been completed (must be completed prior to randomization):
1. 2 weeks (14 days) or 5 half-lives, whichever is shorter, for chemotherapeutic agents, small molecules, and checkpoint inhibitors
2. 3 weeks (21 days) or 5 half-lives, whichever is shorter, for antibody-drug conjugates
3. 4 weeks (28 days) for cell therapies
4. 2 weeks (14 days) for radiation therapy
* Any unresolved and significant toxicity (National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI-CTCAE\] version 5.0) Grade \> 2 from previous anticancer therapy (including radiation therapy), other than alopecia
* Significant cardiovascular disease, including: Cardiac failure New York Heart Association class III or IV; Myocardial infarction, severe or unstable angina within 6 months prior to randomization; History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation)
* Any other medical condition or psychiatric condition that, in the opinion of the Investigator, might interfere with the participant's involvement in the study or interfere with the interpretation of study results
* History of prior malignancy within 2 years prior to randomization (except for adequately treated non-melanoma skin cancer, carcinoma in situ of the breast or cervix, superficial bladder cancer, or early-stage prostate cancer, without evidence of recurrence; participants may or may not be on maintenance therapy)
* Participants who are positive for HBV or HCV with indication of acute or chronic hepatitis (as defined in protocol)
* Radiographic evidence (historical or at screening) of interstitial lung disease or idiopathic pulmonary fibrosis
* Female participants who are pregnant or breastfeeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AVEO Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
The University of Arizona Cancer Center
Tucson, Arizona, United States
University of California Los Angeles
Westwood, Los Angeles, California, United States
Yale School of Medicine - Smilow Cancer Hospital
New Haven, Connecticut, United States
The George Washington University
Washington D.C., District of Columbia, United States
AdventHealth Medical Group Oncology & Hematology at Orlando
Orlando, Florida, United States
Emory University
Atlanta, Georgia, United States
University of Illinois Cancer Center
Chicago, Illinois, United States
University of Kansas Cancer Center
Westwood, Kansas, United States
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, United States
MaineHealth Institute for Research
South Portland, Maine, United States
University of Maryland
Baltimore, Maryland, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Siteman Cancer Center - Washington University
St Louis, Missouri, United States
Northwell Health Cancer Institute
Lake Success, New York, United States
Manhattan Eye, Ear & Throat Hospital
New York, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
University of Cincinnati - UC Health Barrett Cancer Center
Cincinnati, Ohio, United States
Ohio State University, James Cancer Hospital and Solove Research Institute
Columbus, Ohio, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center - Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Medical University of South Carolina (MUSC)
Charleston, South Carolina, United States
MD Anderson Cancer Center
Houston, Texas, United States
Oncology Consultants
Houston, Texas, United States
VCU Massey Cancer Center
Richmond, Virginia, United States
Medical College of Wisconsin - Froedtert Hospital Cancer Center
Milwaukee, Wisconsin, United States
St George Hospital
Kogarah, New South Wales, Australia
St. Vincent's Hospital
Sydney, New South Wales, Australia
Princess Alexandra Hospital
Brisbane, Queensland, Australia
St. John of God Murdoch Hospital
Murdoch, Western Australia, Australia
CHU Liège
Liège, , Belgium
CHU Universite Catholique de Louvain
Namur, , Belgium
Vitaz-Sint-Niklaas Moerland
Sint-Niklaas, , Belgium
University Hospital
Panagyurishte, , Bulgaria
Tom Baker Cancer Centre (Alberta Health Services)
Calgary, Alberta, Canada
Cross Cancer Institute
Edmonton, Alberta, Canada
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
Princess Margaret Cancer Center - University Health Network
Toronto, Ontario, Canada
McGill University Health Centre (MUHC)
Montreal, Quebec, Canada
Fakultni nemocnice Brno
Brno, , Czechia
Masaryk Memorial Cancer Institute
Brno, , Czechia
Fakultni Nemocnice Olomouc
Olomouc, , Czechia
Fakultni Nemocnice Kralovske Vinohrady
Prague, , Czechia
Fakultni nemocnice Bulovka
Prague, , Czechia
Clinique Pasteur - Lanroze- Centre Finistérien de Radiothérapie et d'Oncologie
Brest, , France
Pôle Santé Léonard de Vinci
Chambray-lès-Tours, , France
Centre Léon Bérard
Lyon, , France
Assistance Publique Hopitaux de Marseille (APHM)-Hôpital La Timone
Marseille, , France
Institut Curie
Paris, , France
Hôpital Privé des Côtes d'Armor
Plérin, , France
Institut Gustave Roussy
Villejuif, , France
Charite-Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK) - Medizinische Klinik mit Schwerpunkt Haematologie, Onkologie und Tumorimmunologie
Berlin, , Germany
UNIVERSITÄTSKLINIKUM FREIBURG, Klinik für Innere Medizin I, Schwerpunkt Hämatologie, Onkologie und Stammzelltransplantation
Freiburg im Breisgau, , Germany
Ludwig-Maximilians University
Munich, , Germany
Orszagos Onkologiai Intezet
Budapest, , Hungary
Petz Aladar Country Teaching Hospital
Győr, , Hungary
Josa Andras Oktatokorhaz
Nyíregyháza, , Hungary
University of Pecs - Oncology
Pécs, , Hungary
Szent Lázár Megyei Kórház
Salgótarján, , Hungary
IRCCS Istituto Scienze Neurologiche
Bologna, , Italy
AOU Careggi
Florence, , Italy
IRCCS Istituto Clinico Humanitas - Cancer center
Milan, , Italy
IRCCS Ospedale San Raffaele Milano
Milan, , Italy
Fondazione IRCCS - Istituto Nazionale Tumori - Oncologia
Milan, , Italy
Azienda Ospedaliera Universitaria Maggiore Della Carita Novara
Novara, , Italy
Istituto Oncologico Veneto
Padua, , Italy
IRCCS - ICS Maugeri
Pavia, , Italy
Universita degli Studi di Pavia - Fondazione IRCCS Policlinico San Matteo
Pavia, , Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, , Italy
Antoni van Leeuwenhoek
Amsterdam, , Netherlands
Radboud University Medical Center
Nijmegen, , Netherlands
Centrum Onkologii im. prof. F. Lukaszczyka w Bydgoszczy
Bydgoszcz, , Poland
National Research Institute of Oncology
Gliwice, , Poland
Medisprof Cancer Center
Cluj-Napoca, , Romania
Centrul radioterapie Amethyst Cluj-Napoca
Floreşti, , Romania
Institute of Oncology and Radiology of Serbia
Belgrade, , Serbia
Institute for Oncology Vojvodina
Kamenitz, , Serbia
University Clinical Center Kragujevac
Kragujevac, , Serbia
Keimyung University Dongsan Hospital
Daegu, , South Korea
Korea University Anam Hospital
Seoul, , South Korea
Seoul National University Hospital
Seoul, , South Korea
The Catholic University of Korea, Eunpyeong St. Mary's Hospital
Seoul, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Ajou University Hospital
Suwon, , South Korea
Hospital Universitario Vinalopo
Alicante, , Spain
Institut Catala d'Oncologia - Hospital Duran i Reynals
Badalona, , Spain
UOMI Cancer Center-Clinica Tres Torres
Barcelona, , Spain
Institut Catala d'Oncologia (ICO) - Hospitalet
Barcelona, , Spain
Vall d'Hebron Institut d'Oncologia (VHIO)
Barcelona, , Spain
Hospital universitario Jerez
Cadiz, , Spain
Hospital Universitario La Paz
Madrid, , Spain
Grupo Hospital de Madrid (HM) - Hospital Universitario Madrid Sanchinarro - Centro Integral Oncologico Clara Campal (CIOCC)
Madrid, , Spain
Hospital Universitario de Torrejón
Madrid, , Spain
Hospital Quironsalud Malaga
Málaga, , Spain
Hospital Universitario Marques de Valdecilla
Santander, , Spain
Hospital Clinico Universitario de Valencia (CHUV)
Valencia, , Spain
Changhua Christian Hospital
Changhua, , Taiwan
Chang Gung Memorial Hospital - Kaohsiung
Kaohsiung City, , Taiwan
China Medical University Hospital (CMUH)
Taichung, , Taiwan
National Cheng-Kung University Hospital
Tainan City, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Chang Gung Memorial Hospital - Linkou
Taoyuan District, , Taiwan
NHS Grampian - Aberdeen Royal Infirmary
Aberdeen, , United Kingdom
The Royal Marsden NHS Foundation Trust
London, , United Kingdom
Sarah Cannon Research Institute
London, , United Kingdom
City Hospital Nottingham
Nottingham, , United Kingdom
The Royal Marden Hospital, Surrey
Sutton, , United Kingdom
Torbay Hospital
Torquay, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AV-299-23-301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.